methyllycaconitine has been researched along with Body Weight in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kanaoka, Y; Kataoka, Y; Koga, M; Kubo, N; Ohishi, K; Ohkido, Y; Sugiyama, K; Yamauchi, A | 1 |
Camarasa, J; Chipana, C; Escubedo, E; Pérez-Sánchez, M; Pubill, D | 1 |
2 other study(ies) available for methyllycaconitine and Body Weight
Article | Year |
---|---|
Varenicline aggravates plaque formation through α7 nicotinic acetylcholine receptors in ApoE KO mice.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Apolipoproteins E; Benzazepines; Body Weight; Cardiovascular Diseases; Cholesterol; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotinic Agonists; Plaque, Atherosclerotic; Quinoxalines; Varenicline | 2014 |
Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antioxidants; Blotting, Western; Body Temperature; Body Weight; Calcium; Cell Membrane; Central Nervous System Stimulants; Dopamine; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Immunohistochemistry; Isoquinolines; Male; Methamphetamine; Mice; Microglia; Motor Activity; Neostriatum; Neurotoxicity Syndromes; Nicotinic Antagonists; Radioligand Assay; Reactive Oxygen Species; Receptors, Nicotinic; Synaptic Vesicles; Synaptosomes; Tyrosine 3-Monooxygenase | 2005 |